文献速递支持与姑息治疗

晚期癌症早期系统整合姑息治疗随机对照试验

Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial.
PubMed 文献 · Lancet Oncol · 2018-02-03

这项随机对照试验纳入186例晚期实体瘤患者,比较早期系统整合姑息治疗与标准肿瘤治疗。

要点

  • 早期系统整合姑息治疗可改善晚期癌症患者12周生活质量。
  • 即使已有心理社会支持,整合姑息治疗仍优于按需咨询。
  • 肿瘤科医生应与专业姑息治疗团队协作提升患者生活质量。

核心结论

  • 早期系统整合姑息治疗可提高晚期癌症患者的生活质量。
  • 即使常规肿瘤治疗已包含心理社会支持,整合姑息治疗仍优于按需姑息咨询。

研究设计与样本

  • 随机对照试验,2013年4月29日至2016年2月29日筛查468例,纳入186例晚期实体瘤患者。
  • 患者随机分入早期系统整合姑息治疗组(92例)或标准肿瘤治疗组(94例)。
  • 主要终点为12周时EORTC QLQ C30总体健康状况/生活质量量表变化,按意向治疗分析。

主要发现

  • 12周依从率:整合组71%(65例),标准组72%(68例)。

临床怎么用

  • 对晚期实体瘤患者,应在肿瘤治疗中早期系统整合姑息治疗,而非仅按需提供姑息咨询。
  • 肿瘤科医生与专业姑息治疗团队协作,以提升晚期癌症患者生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefit of early integration of palliative care into oncological care is suggested to be due to increased psychosocial support. In Belgium, psychosocial care is part of standard oncological care. The aim of this randomised controlled trial is to examine whether early and systematic integration of palliative care alongside standard psychosocial oncological care provides added benefit compared with usual care. METHODS: In this randomised controlled trial, eligible patients were 18 years or older, and had advanced cancer due to a solid tumour, an European Cooperative Oncology Group performance status of 0-2, an estimated life expectancy of 12 months, and were within the first 12 weeks of a new primary tumour or had a diagnosis of progression. Patients were randomly assigned (1:1), by block design using a computer-generated sequence, either to early and systematic integration of palliative care into oncological care, or standard oncological care alone in a setting where all patients are offered multidisciplinary oncology care by medical specialists, psychologists, social workers, dieticians, and specialist nurses. The primary endpoint was change in global health status/quality of life scale assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ C30) at 12 weeks. The McGill Quality of Life Questionnaire (MQOL), which includes the additional existential wellbeing dimension, was also used. Analysis was by intention to treat. This trial is ongoing, but closed for accrual, and is registered with ClinicalTrials.gov, number NCT01865396. FINDINGS: From April 29, 2013, to Feb 29, 2016, we screened 468 patients for eligibility, of whom 186 were enrolled and randomly assigned to the early and systematic palliative care group (92 patients) or the standard oncological care group (94). Compliance at 12 weeks was 71% (65 patients) in the intervention group versus 72% (68) in the control group. The overall quality of life score at 12 weeks, by the EORTC QLQ C30, was 54·39 (95% CI 49·23-59·56) in the standard oncological care group versus 61·98 (57·02-66·95) in the early and systematic palliative care group (difference 7·60 [95% CI 0·59-14·60]; p=0·03); and by the MQOL Single Item Scale, 5·94 (95% CI 5·50-6·39) in the standard oncological care group versus 7·05 (6·59-7·50) in the early and systematic palliative care group (difference 1·11 [95% CI 0·49-1·73]; p=0.0006). INTERPRETATION: The findings of this study show that a model of early and systematic integration of palliative care in oncological care increases the quality of life of patients with advanced cancer. Our findings also show that early and systematic integration of palliative care is more beneficial for patients with advanced cancer than palliative care consultations offered on demand, even when psychosocial support has already been offered. Through integration of care, oncologists and specialised palliative care teams should work together to enhance the quality of life of patients with advanced cancer. FUNDING: Research Foundation Flanders, Flemish Cancer Society (Kom Op Tegen Kanker).

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Vanbutsele G, Pardon K, Van Belle S, et al. Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial. Lancet Oncol. 2018. PMID: 29402701. doi:10.1016/S1470-2045(18)30060-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。